Azetidine and pyrrolidine PARP1 inhibitors and uses thereof
Described herein are azetidine and pyrrolidine PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer and are of Formula I(b)
1. A compound that is:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
2. A compound that is:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
3. A compound that is:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
4. The compound of claim 1 , that is:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , that is:
6. The compound of claim 2 , that is:
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 2 , that is:
8. The compound of claim 3 , that is:
or a pharmaceutically acceptable salt thereof.
9. The compound of claim 3 , that is:
10. A pharmaceutical composition comprising a compound of claim 4 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
11. A pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable excipient.
12. A pharmaceutical composition comprising a compound of claim 6 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
13. A pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable excipient.
14. A pharmaceutical composition comprising a compound of claim 8 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
15. A pharmaceutical composition comprising a compound of claim 9 and a pharmaceutically acceptable excipient.